Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 430,037
  • Shares Outstanding, K 84,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,750 K
  • EBIT $ -9 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.48

Options Overview Details

View History
  • Implied Volatility 371.83% (-275.69%)
  • Historical Volatility 81.62%
  • IV Percentile 58%
  • IV Rank 30.52%
  • IV High 812.34% on 12/09/25
  • IV Low 178.35% on 11/20/25
  • Expected Move (DTE 27) 0.34 (6.71%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 69
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 1,049
  • Open Int (30-Day) 7,364
  • Expected Range 4.73 to 5.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.13
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.43 +47.81%
on 11/21/25
5.21 -2.62%
on 12/17/25
+1.39 (+37.77%)
since 11/19/25
3-Month
3.43 +47.81%
on 11/21/25
5.21 -2.62%
on 12/17/25
+0.98 (+23.96%)
since 09/19/25
52-Week
2.30 +120.43%
on 04/04/25
5.21 -2.62%
on 12/17/25
+1.95 (+62.24%)
since 12/19/24

Most Recent Stories

More News
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that the FDA...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate in December Investor Conferences

JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

-  Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study - - Newly received r adioactive m aterial l icense for New Hampshire f acility ...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

-  Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ® , the innovative alpha-radiation cancer therapy designed for potent...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate in Five September Investor Conferences

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)

Business Summary

Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM.

See More

Key Turning Points

3rd Resistance Point 5.35
2nd Resistance Point 5.22
1st Resistance Point 5.15
Last Price 5.07
1st Support Level 4.95
2nd Support Level 4.82
3rd Support Level 4.75

See More

52-Week High 5.21
Last Price 5.07
Fibonacci 61.8% 4.10
Fibonacci 50% 3.75
Fibonacci 38.2% 3.41
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar